We’re pleased to share with you that the FDA has lifted the clinical hold on IGNITE DMD.
- Activities to Resume Enrollment in IGNITE DMD Phase I/II Clinical Trial are Underway
- Conference Call Scheduled for Today at 8:30 A.M. ET
- Data Reinforce Potential of SGT-001 as an Important Treatment Candidate for DMD -
- Company Continues to Advance Gene Therapy Portfolio -
Solid Biosciences today announced that new preclinical data from its DMD programs will be presented at the 21st Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT).
Please subscribe to receive our latest news